- E-postBeryl.Leirvaag@uib.no
- Telefon+47 55 97 64 44
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 BergenRom1417, etg. 1M Laboratoriebygget
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Medicine. 15 sider.
- (2023). Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. JCO Precision Oncology (JCO PO). 10 sider.
- (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 1-10.
- (2016). Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice. 4 sider.
- (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 1553-1564.
- (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 sider.